液体型缓控释注射剂的研究进展

occludens toxin[J ].Eur J Pharm Biopharm ,2001,52(2):1452150.

[11]Bernkop 2Schnurch A.The use of inhibitory agents to over 2

come the enzymatic barrier to perorally administered therapeu 2tic peptides and proteins[J ].J Controlled Release ,1998,52(122):1216.

[12]Ramdas M ,Dileep KJ ,Anitha Y,et al.Alginate encapsu 2

lated bioadhesive chitosan microspheres for intestinal drug de 2livery[J ].J Biomater Appl ,1999,13(4):2902296.[13]Bernkop 2Schn ürch A ,K rauland A ,Valenta C.Development

and in vitro evaluation of drug delivery system based on chi 2tosan 2E DT A BBI conjugate[J ].J Drug Target ,1998,6(3):2072214.

[14]G uggi D ,K rauland A H ,Bernkop 2Schnurch A.Systemic

peptide delivery via the stomach :in viv o evaluation of an oral dosage form for salm on calcitonin[J ].J Controlled Release ,2003,92(122):1252135.

[15]T ozaki H ,Nishioka J ,K om oike J ,et al.Enhanced abs orp 2

tion of insulin and (Asu (1,7))eel 2calcitonin using novel a 2zopolymer 2coated pellets for colon 2specific drug delivery[J ].J Pharm Sci ,2001,90(1):89297.

[16]H osny E A ,el 2Bag ory I M ,al 2Jenoobi F I.Enteric 2coated

insulin capsules :a combination with or a replacement of oral hypoglycaemic drugs[J ].Boll Chim Farm ,2002,141(5):3792384.

[17]Mathiowitz E ,Jacob J S ,Jong Y S ,et al.Biologically Erod 2

able M icrospheres as P otential Oral Drug Delivery Systems [J ].Nature ,1997,386(6623):4102414.

[18]Carcabos o A M ,Hernandez R M ,Igartua M ,et al.Immune

response after oral administration of the encapsulated malaria

synthetic peptide SP f66[J ].Int J Pharm ,2003,260(2):2732282.

[19]Partidos C D ,V ohra P ,Jones D H ,et al.Induction of cyto 2

toxic T 2cell responses following oral immunization with syn 2thetic peptides encapsulated in P LG microparticles [J ].J Controlled Release ,1999,62(3):3252332.

[20]T akeuchi H ,Y amam oto H ,K awashima Y.Mucoadhesive

nanoparticulate systems for peptide drug delivery [J ].Adv Drug Del Rev ,2001,47(1):39254.

[21]Pan Y,Li YJ ,Zhao H Y,et al.Bioadhesive polysaccharide

in protein delivery system :chitosan nanoparticles im prove the intestinal abs orption of insulin in viv o [J ].Int J Pharm ,2002,249(122):1392147.

[22]Sakuma S ,Suzuki N ,K ikuchi H ,et al.Oral peptide deliv 2

ery using nanoparticles com posed of novel graft copolymers having hydrophobic backbone and hydrophilic branches [J ].Int J Pharm ,1997,149(1):932106.

[23]Sakuma S ,Suzuki N ,Sudo R ,et al.Optimized chemical

structure of nanoparticles as carriers for oral delivery of salm on calcitonin[J ].Int J Pharm ,2002,239(122):1852195.

[24]I wanaga K,Ono S ,Narioka K,et al.Oral delivery of insulin

by using sur face coating lipos omes :Im provement of stability of insulin in GI tract [J ].Int J Pharm ,1997,157(1):73280.

[25]Watnasirichaikul S ,Rades T ,Tucker I G,et al.In 2vitro re 2

lease and oral bioactivity of insulin in diabetic rats using nanocapsules dispersed in biocom patible microemulsion[J ].J Pharm Pharmacol ,2002,54(4):4732480.

[接受日期]　2004204228

3

　通讯作者:　周建平,教授,博士生导师;研究方向:　药物新剂型和新技术;

T el :025*********;　E 2m ail :zhoujianp60@

液体型缓控释注射剂的研究进展

谢　鹤,　周建平3

(中国药科大学药剂学教研室,江苏南京210009)

[摘　要]　按照注射液中粒子大小对液体型缓、控释注射剂进行分类,概述了缓控释注射剂的发展与基本特

点,着重阐述在体凝胶、纳米囊、纳米粒、乳剂及微球、微囊等注射剂的制备方法、释药特性。液体型缓、控释注射剂作为一种新型药物输注系统,是国内外药物制剂研究的一个重要方向,具有广阔的开发前景。

[关键词]　缓控释注射剂;微球;纳米粒;乳剂

[中图分类号]　R944111 [文献标识码]　A [文章编号]　1001-5094(2004)10-0441-06